A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer’s disease and agitated behaviours: the HTA-SYMBAD trial

Sube Banerjee; Nicolas Farina; Catherine Henderson; Juliet High; Susan Stirling; Lee Shepstone; Julia Fountain; Clive Ballard; Peter Bentham; Alistair Burns; Chris Fox; Paul Francis; Robert Howard; Martin Knapp; Iracema Leroi; Gill Livingston; Ramin Nilforooshan; Shirley Nurock; John O’brien; Annabel Price; Alan J. Thomas; Ann Marie Swart; Tanya Telling; Naji Tabet

doi:10.3310/vpdt7105

A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer’s disease and agitated behaviours: the HTA-SYMBAD trial

Sube Banerjee^*
, Nicolas Farina
, Catherine Henderson
, Juliet High
, Susan Stirling
, Lee Shepstone
, Julia Fountain
, Clive Ballard
, Peter Bentham
, Alistair Burns
, Chris Fox
, Paul Francis
, Robert Howard
, Martin Knapp
, Iracema Leroi
, Gill Livingston
, Ramin Nilforooshan
, Shirley Nurock
, John O’brien
, Annabel Price

Alan J. Thomas, Ann Marie Swart, Tanya Telling, Naji Tabet

^*Corresponding author for this work

University of Sussex
The London School of Economics and Political Science
University of East Anglia
Sussex Partnership NHS Foundation Trust
University of Exeter
Birmingham and Solihull Mental Health NHS Foundation Trust
University of Manchester
University College London
Trinity College Dublin
Surrey and Borders Partnership NHS Foundation Trust
Alzheimer's Society
University of Cambridge
Cambridgeshire and Peterborough NHS Foundation Trust
Newcastle University

Research output: Book/Report › Commissioned report › peer-review

63 Downloads (Pure)

Original language	English
DOIs	https://doi.org/10.3310/vpdt7105
Publication status	Published - Oct 2023

Access to Document

10.3310/vpdt7105

2023 Banerjee et al

Cite this

Banerjee, S., Farina, N., Henderson, C., High, J., Stirling, S., Shepstone, L., Fountain, J., Ballard, C., Bentham, P., Burns, A., Fox, C., Francis, P., Howard, R., Knapp, M., Leroi, I., Livingston, G., Nilforooshan, R., Nurock, S., O’brien, J., ... Tabet, N. (2023). A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer’s disease and agitated behaviours: the HTA-SYMBAD trial. https://doi.org/10.3310/vpdt7105

@book{38d39c33069141609208236b1ff4bdfc,

title = "A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer{\textquoteright}s disease and agitated behaviours: the HTA-SYMBAD trial",

author = "Sube Banerjee and Nicolas Farina and Catherine Henderson and Juliet High and Susan Stirling and Lee Shepstone and Julia Fountain and Clive Ballard and Peter Bentham and Alistair Burns and Chris Fox and Paul Francis and Robert Howard and Martin Knapp and Iracema Leroi and Gill Livingston and Ramin Nilforooshan and Shirley Nurock and John O{\textquoteright}brien and Annabel Price and Thomas, \{Alan J.\} and Swart, \{Ann Marie\} and Tanya Telling and Naji Tabet",

year = "2023",

month = oct,

doi = "10.3310/vpdt7105",

language = "English",

}

Banerjee, S , Farina, N, Henderson, C, High, J, Stirling, S, Shepstone, L, Fountain, J, Ballard, C, Bentham, P, Burns, A, Fox, C, Francis, P, Howard, R, Knapp, M, Leroi, I, Livingston, G, Nilforooshan, R, Nurock, S, O’brien, J, Price, A, Thomas, AJ, Swart, AM, Telling, T & Tabet, N 2023, A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer’s disease and agitated behaviours: the HTA-SYMBAD trial. https://doi.org/10.3310/vpdt7105

A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer’s disease and agitated behaviours: the HTA-SYMBAD trial. / Banerjee, Sube ; Farina, Nicolas; Henderson, Catherine et al.
2023.

Research output: Book/Report › Commissioned report › peer-review

TY - BOOK

T1 - A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer’s disease and agitated behaviours: the HTA-SYMBAD trial

AU - Banerjee, Sube

AU - Farina, Nicolas

AU - Henderson, Catherine

AU - High, Juliet

AU - Stirling, Susan

AU - Shepstone, Lee

AU - Fountain, Julia

AU - Ballard, Clive

AU - Bentham, Peter

AU - Burns, Alistair

AU - Fox, Chris

AU - Francis, Paul

AU - Howard, Robert

AU - Knapp, Martin

AU - Leroi, Iracema

AU - Livingston, Gill

AU - Nilforooshan, Ramin

AU - Nurock, Shirley

AU - O’brien, John

AU - Price, Annabel

AU - Thomas, Alan J.

AU - Swart, Ann Marie

AU - Telling, Tanya

AU - Tabet, Naji

PY - 2023/10

Y1 - 2023/10

UR - https://pearl.plymouth.ac.uk/pms-research/833/

U2 - 10.3310/vpdt7105

DO - 10.3310/vpdt7105

M3 - Commissioned report

BT - A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer’s disease and agitated behaviours: the HTA-SYMBAD trial

ER -

A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer’s disease and agitated behaviours: the HTA-SYMBAD trial

Access to Document

Other files and links

Cite this